Polar solvents: a novel class of antineoplastic agents.
Polar solvents: a novel class of antineoplastic agents.
复制标题
极性溶剂：一类新型抗肿瘤剂。
DOI：
--
复制
发表时间：
1984
影响因子：
45.3
通讯作者：
D. Dexter
中科院分区：
文献类型：
--
作者：
E. Spremulli;D. Dexter
几十年来，人们已经知道某些鼠和人类癌症可以自发地成熟为良性组织。这些观察结果促使研究人员尝试使用生物物质或化学物质诱导癌细胞的更正常或良性分化状态。极性溶剂，包括二甲基亚砜，二甲基甲酰胺，和一甲基甲酰胺已被证明是很好的诱导剂的成熟事件在小鼠和人类癌细胞。此外，几个实验室已经证明，极性溶剂抑制裸鼠中人肿瘤异种移植物的生长。这些发现导致单甲基甲酰胺进入美国和欧洲的I期临床试验。临床前工作进一步表明，极性溶剂可能是与常规治疗方式组合的有用药剂。使用诸如单甲基甲酰胺的药物可以将肿瘤细胞转化为良性细胞而不是杀死肿瘤细胞，这代表了与标准细胞毒性化疗的重要概念偏离。成熟剂治疗的使用应被视为癌症治疗方案设计中的重要新进展。
It has been known for many decades that certain murine and human cancers can spontaneously mature to benign tissue. These observations have stimulated investigators to attempt to induce a state of more normal or benign differentiation in cancer cells using biologic substances or chemicals. Polar solvents including dimethylsulfoxide, dimethylformamide, and monomethylformamide have proven to be good inducers of maturational events in murine and human cancer cells. Moreover, several laboratories have demonstrated that polar solvents inhibit the growth of human tumor xenografts in nude mice. These findings have resulted in the entry of monomethylformamide into phase I clinical trials in America and Europe. Preclinical work further suggests that polar solvents may be useful agents in combination with conventional treatment modalities. The use of drugs such as monomethylformamide that can convert neoplastic cells to benign cells rather than kill the tumor cells represents an important conceptual departure from standard cytotoxic chemotherapy. The use of maturational-agent therapy should be considered as an important new development in the design of cancer treatment protocols.